# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Georgia O'Keeffe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET011-SYN-TD
- Date: 1968-05-07
- Fictional facility: St. Posthumous Health Center
- Fictional author: Wendell Ashby, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Third loading injection and end-of-loading review, left eye. **S**

## History of present illness

Ms. O'Keeffe returns four weeks after her second injection, eight weeks after starting treatment. Straight lines look nearly straight again with the left eye, and she can read newspaper headlines and judge color in the studio better than in March. She has had no pain, redness, or loss of vision after either injection. Daily Amsler checks show no change in the right eye. She takes the AREDS2 supplement daily. Her low-vision rehabilitation evaluation took place this month, and the home visit and driving assessment are under way. **S**

| Element | Detail |
|---|---|
| Interval change | Distortion nearly gone in the left eye; color judgment better |
| Injection tolerance | No pain, redness, or vision loss after two injections |
| Amsler grid | Daily checks; right eye unchanged |
| Low-vision rehabilitation | Evaluation done; home visit and driving assessment under way |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Slight residual blur in the left eye; no pain, flashes, or floaters |
| Constitutional | Negative | Weight stable; good energy |
| Musculoskeletal | Negative | No falls |
| Psychiatric | Negative | Mood good; painting daily |

4 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/70 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 56 kg; BMI 20.6 kg/m². All vital signs are synthetic.

Best-corrected visual acuity, left eye (ETDRS letters): 69 (low); Central subfield thickness by OCT, left eye: 274 um; Intraocular pressure, left eye: 14 mmHg. All results are synthetic.

## Change since baseline

- Best-corrected visual acuity, left eye (ETDRS letters): 56 (low) at baseline, 69 (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| Visual acuity | Best-corrected 69 letters left, up from 55 |
| Intraocular pressure | 14 mmHg left before injection |
| Anterior segment | Quiet |
| Dilated fundus, left eye | Lesion flat, with no fluid or hemorrhage |
| Dilated fundus, right eye | Large drusen unchanged; no fluid or hemorrhage |
| OCT, left eye | Dry macula; central subfield thickness 274 µm |
| After injection, left eye | Optic nerve head perfused; counts fingers; no pain |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Neovascular age-related macular degeneration, left eye, dry after loading** (H35.3221). Loading phase complete. Acuity has risen 14 letters (55 to 69) and the macula is dry (central subfield thickness 274 µm), meeting both loading goals. Third injection given today without complication. **S**
   - Begin treat-and-extend: next injection in eight weeks, aflibercept's standard interval after loading.
   - Extend by two weeks at each visit while the macula stays dry; shorten if fluid returns.
2. **Intermediate dry age-related macular degeneration, right eye** (H35.3112). Stable. **S**
   - Continue the AREDS2 supplement and daily Amsler checks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Best-corrected visual acuity (ETDRS letters) | Every injection visit | Completed today | Left 69 letters, up 14 from baseline; loading goal met |
| Imaging | Optical coherence tomography of the macula | Every injection visit | Completed today | Left eye dry; central subfield thickness 274 µm |
| Examination | Intraocular pressure before and after injection | Every injection visit | Completed today | Before injection 14 mmHg left; after injection, optic nerve perfused and counting fingers |
| Examination | Dilated examination of the fellow (right) eye | Every injection visit | Completed today | Large drusen unchanged; no fluid |
| Medication safety | Intravitreal injection safety | Every injection visit | Completed today | No complication after three injections; last loading dose today |
| Self-management | Teaching on warning signs of endophthalmitis and retinal detachment | Every injection visit | Completed today | Reviewed again before the longer interval |
| Self-management | Daily home Amsler grid, each eye | Daily | Completed today | Daily checks recorded; no change in the right eye |
| Medication safety | AREDS2 supplement for intermediate AMD | Daily, long term | Completed today | Taking it daily |
| Referral | Low-vision rehabilitation, with home fall-risk review and a driving assessment | Once central vision is reduced; review as vision changes | Referred | Evaluation done this month; home visit and driving assessment under way |
| Survey | Depression screen (PHQ-2) | At follow-up, because vision loss raises the risk of depression; periodically at 65 or older | Due | Planned at the July primary care review |

## Goal progress

- Gain at least 10 ETDRS letters in the left eye by the end of the loading phase. Outcome by 1968-05-07: Left eye improved from 55 to 69 letters after three injections. **S**
- Dry macula on OCT (central subfield thickness below 300 um, no fluid) by the end of the loading phase. Outcome by 1968-05-07: Central subfield thickness fell from 418 to 274 um with no fluid. **S**
- Check the Amsler grid daily for each eye and report any change the same day. In progress; target 1968-07-02. **S**
- Complete a low-vision rehabilitation evaluation and set up studio lighting and magnification by the July visit. In progress; target 1968-07-02. **S**

## Guideline basis

- Age-Related Macular Degeneration Preferred Practice Pattern (2024), American Academy of Ophthalmology
- CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026), Aether Forge

## Follow-up

- Retina visit in eight weeks, with the primary care review of vision rehabilitation on the same day. **S**
- Next scheduled visit 1968-07-02: treat-and-extend retina visit and primary care review of vision rehabilitation. **S**
